Issue link: https://www.e-digitaleditions.com/i/1534558
10 BioPharm International ® Next-Generation Biotherapeutics April 2025 www.biopharminternational.com Oncology i ly, t hese a re si ng le-dose t reat ment s t h at we're getting," Bock says. "These cell responses can per- sist in the body for months, and sometimes we've seen not ra re ex a mples of t hese cel l s persi st i ng for even years." "Your immune cells are actually what's sur vey- ing your body," Hein explains. "They can prevent cancers. They can find early cancers and eliminate it ent irely. And so, if you look at a t umor, rea l ly, that's a failure of your immune system in some way, it hasn't been able to do that job. When you take a cell therapy, then you're actually harvesting the im- mune cells from the patient and then boosting them in some way to help them do that job that they're supposed to do." Cell therapies for cancer treatment have been fo- cused on CAR T-cells, according to Bock, but these treat only a small number of cancer types, such as blood cancers. "Another emerging treatment option is tumor-infiltrating lymphocytes (TILs), which are focused on treating solid tumors, such as lung and cervical cancers, a step forward in fighting 90% of cancers," says Bock. "[For TILs], we take circulating lymphocytes and engineer them to attack very spe- cific tumors," Bock explains. "TILs have been around for decades, especially in academic centers, and have a slightly different ap- proach, where we take a piece of the tumor and ex- tract the cells, the immune cells that [have] already found their way into the tumor and are presumably fighting that tumor, and then we can have methods to expand, in some ways, rejuvenate those cells to large numbers and then reinfuse those to the same patient," says Bock. "Another really exciting aspect about TILs is that they have inherent specificity for the tumor that allows us the opportunity to further genetically engineer them for improved fitness, per- sistence, or durability." Bock is excited about the regulatory pathway cre- ated by the first commercially approved TIL which ha s fostered development of t he genet ica l ly en- gineered TILs that are currently in clinical trials. "Some companies have shown some ver y exciting clinical results for those thus far," Bock says. "Ob- sidian Therapeutics comes to mind, [which] released some nice clinical data last year, and is a par tner with CTMC. Others are in the clinic with new ge- netic engineering or gene editing approaches that I think are going to unlock further potential in the TIL field in the years to come. That should help us expand TILs from primarily being focused on mela- noma to other solid tumor indications [such as] lung cancer, or, hopef ully, even more dif f icult-to-treat cancers [such as] pancreatic cancer." Because cell therapies are complicated and are liv- ing cells taken from a person and then engineered to be reproducible and reintroduced to that person, there is variabilit y from patient to patient, which creates challenges for manufacturing, says Bock. Good science and engineering are necessary to de- sign robust processes, according to Bock. The cir- cular supply chain of cell therapies, however, is one way to deal with the complexity. "With cell therapies, the supply chain really be- gins and ends with the same patient," Bock says. "And so, if we take into account that shape, if you will, of the supply chain, how can we engineer man- ufacturing to take that into account?" To simplif y the supply chain, CTMC has positioned its manufac- turing facility right next to the MD Anderson Cancer Center, as well as other hospitals. "We take all the logistics out of shipping starting material and ship- ping the final product back to the hospital. We don't need airplanes. We don't need to worry about travel schedules or anything, or even the amount of time that that takes. We can essentially get in a shuttle bus and be back and forth with the patient sample in a matter of minutes." Hei n poi nts to t he i ndust r y i nvest ment i n un- dersta nding a nd shor ten ing t he ma nufact ure of cell therapies, "understanding how to minimally manipulate those cells to keep them as healthy as possible, as close to their sort of native vigor as you can from the patient" as a way to combat the com- plexity. "What's really exciting, and I think some- what under-appreciated, is the implementation of more rapid testing and release processes, so we can do all the same tests that we have to do to ensure the quality and vigor of the product, but do it more quickly, so that way we can bring the product back to the patient as quickly as possible." Advancements in automation will also help over- come some of the challenges of cell therapies, ac- cording to Hein. "The combination of an automated platform, automated manufacturing alongside re- Scalability of gene therapies is also a factor in manufacturing, especially with cancer treatments.